Replies to post #164477 on Biotech Values

[DewDiligence]

PRAN starts open-label extension of IMAGINE study in AD:

http://finance.yahoo.com/news/prana-doses-first-patient-pbt2-130000304.html

Patients who have completed the full 12-month term of the IMAGINE trial are eligible for participation in the open-label Extension study. All participants in the Extension study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months.

[goodJohnhunting]

Kadaicher,

Pran. Market cap even now only $100m. Just the Huntington's DMD market is estimated as the best part of $1B. I have looked at the science hard and can see some good reasons why this should work in HD, at least to some extent. More so in AD. I don't regard it as a lottery ticket at all. Don't expect much agreement.
So far I intend to let it ride, and I have a pretty big(for me) bet on here.

Do you know where or who might be able to differentiate the reasoning of why PBT2 might be more effective in AD, as opposed to HD? I'm looking to get a better understanding of the science, as this is an area of medicine I've only experienced in passing. I'd appreciate the help..

All the best,
John